Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations

Investor Conference on FY2018 2Q Financial Results

Jul 27, 2018

Aug 03: Established ESG information site “ESG at Chugai”
Jul 30: Webcast of Investor Conference on FY2018 2Q Financial Results
Jul 27: Posted Corporate Governance Reports
Jul 27: Investor Conference on FY2018 2Q Financial Results
Jul 26: Financial Results for Second Quarter of Fiscal Year 2018 (January - June, 2018)

More

Aug 03

Anti-CD20 Monoclonal Antibody “RITUXAN^®,”
Application for Approval of Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia

[

PDF 71KB]

Jul 26

Announcement of Business Expansion of
Chugai Pharmabody Research Pte. Ltd., Chugai’s Research Subsidiary

[

PDF 156KB]

Jul 26

Organizational and Personnel Changes

[

PDF 227KB]

Jul 26

Chugai Enters into Comprehensive Partnership Agreement with Preferred Networks

[

PDF 68KB]

Jul 26

Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APls

[

PDF 99KB]

More

Management Policy

TSE Code:4519

Share Graph

Annual Report 2017 (Integrated Edition Including CSR Report)
[ 9.9MB]

Supplementary Materials

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.